Miscellaneous Ocular Agents

Tepezza Supply Shortage Expected Soon

As both the vaccine and Tepezza are being manufactured at Catalent, the government has prioritized the manufacturing of the vaccine thereby resulting in cancellation of previously contracted Tepezza orders.

Beovu Labeling Updated With Additional Safety Information

The Food and Drug Administration (FDA) has approved updated labeling for Beovu® (brolucizumab; Novartis) to include additional safety information regarding the risk of retinal vasculitis and retinal vascular occlusion.  Beovu received FDA approval in October 2019 for the treatment of wet age-related macular degeneration (wet AMD). The Warnings and Precautions section has been updated with…